Pharma BD Deal Intelligence
"Based on their history Diabetic Investor cannot imagine anyone reasonably believing that Roche will be successful here" — skeptical of the deal given Roche's…
Roche cited an 11%+ growth rate in the global insulin delivery market and noted that 'patients new to pumps in the U.S. increasingly favor patch-pump systems'…
"With this acquisition we will broaden our portfolio of innovative insulin delivery technologies and strengthen our position as a leading player in the…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Roche acquired Israeli drug-delivery firm Medingo for $160M, gaining Solo wearable insulin patch pump technology.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Medingo Ltd. (this deal) | 2010 | $160M | 25 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2010 deals · Roche Holding AG deals · Metabolic deals